Brain

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

First Parkinson’s Patients Treated in Landmark Phase 2 Trial of Dapansutrile – Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases

NEW YORK, March 24, 2026 /PRNewswire/ -- Olatec Therapeutics, Inc. ("Olatec"), developing one of the most clinically advanced specific oral...

Unprecedented Coalition of Athletes and Physicians Launches Utah’s First Health Club to Guarantee Measurable Results

Integrated health platform combines diagnostics, performance training, and precision medicine to deliver measurable, data-driven wellness outcomes under one roof BOUNTIFUL,...

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

DUBLIN--(BUSINESS WIRE)--$PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on...

Varian TrueBeam Receives FDA Clearance for Low-Dose Radiotherapy for Adults with Medically Refractory Osteoarthritis

PALO ALTO, Calif.--(BUSINESS WIRE)--#varian--Siemens Healthineers announced that its Varian TrueBeam radiotherapy systems, which include TrueBeam, TrueBeam STx, VitalBeam, and Edge,...

error: Content is protected !!